Baxter launches NUMETA G13E in Europe for preterm newborns at risk for malnutrition





Baxter International Inc a global leader in PN therapy, announced the European launch of NUMETA G13E 300 mL, the only ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm infants (less than 37 weeks gestation age) who are at high risk for infection and malnutrition1 in the early hours and days of their lives.

The announcement was made during the 38th ESPEN (The European Society for Clinical Nutrition and Metabolism) Congress in Copenhagen, Sept. 17-20, with recognition that the first preterm patients have received PN therapy on NUMETA G13E in Sweden.

NUMETA G13E is indicated for PN administration in preterm newborn infants when oral or enteral nutrition is not possible, insufficient or contraindicated. NUMETA G13E addresses an important medical need to support preterm neonatal patients who have acute nutritional requirements by providing a balanced formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system that was pioneered by Baxter.

“Baxter’s NUMETA G13E is a well-balanced, ready-to-use formula in a triple-chamber system that simplifies the preparation process for healthcare workers and helps reduce the potential risk to patients of infection and dosing errors,” said Brik Eyre, president of Baxter's Hospital Products business. “NUMETA G13E is truly innovative nutritional therapy for preterm babies – among the most susceptible patients – when time and safety are critical factors to their care.”

NUMETA G13E is designed for activation and administration at the bedside. Research indicates ready-to-use PN may reduce the potential risk of medication errors and associated infections.2 NUMETA G13E was reformulated to meet the current pediatric nutritional guidelines developed by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and ESPEN.

Baxter’s NUMETA G13E has Marketing Authorization from the Competent Authorities in 15 Western European countries, including Austria, Belgium, France, Germany, Ireland, Malta Netherlands, Poland, Switzerland, the U.K., and the Nordics where the launch initiated. Baxter plans to continue pursuing regulatory approvals and launching NUMETA G13E globally, including in additional European countries and Latin America in 2017.

Baxter offers additional pediatric triple-chamber PN solutions in Europe and select Latin American countries, including NUMETA G16E 500mL for term infants and toddlers (term infants through two years of age); and NUMETA G19E 1,000mL for children and adolescents (2-18 years of age).

About Baxter International Inc.
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

Reference:
1Koletzko B, Goulet O, Hunt J, et al. ESPGHAN / ESPEN Guidelines on Paediatric Parenteral Nutrition. JPGN. 2005.
2Riskin A, Shiff Y, Shamir R. Parenteral Nutrition in Neonatology – To Standardize or Individualize? IMAJ 2006;8:641-645.